MX2020009462A - Procesos para la preparación de compuestos de pirimidinilciclopentano. - Google Patents

Procesos para la preparación de compuestos de pirimidinilciclopentano.

Info

Publication number
MX2020009462A
MX2020009462A MX2020009462A MX2020009462A MX2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A
Authority
MX
Mexico
Prior art keywords
preparation
sup
flexible substrate
wearable
useful
Prior art date
Application number
MX2020009462A
Other languages
English (en)
Inventor
Michelangelo Scalone
Hans Iding
Reinhard Reents
Francis Gosselin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020009462A publication Critical patent/MX2020009462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se relaciona con un proceso para la preparación de un compuesto de fórmula (I), donde R1 es como se define en la presente, que es útil como un intermediario en la preparación de los compuestos farmacéuticos activos.
MX2020009462A 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano. MX2020009462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13193030 2013-11-15
PCT/US2014/065567 WO2015073739A1 (en) 2013-11-15 2014-11-13 Processes for the preparation of pyrimidinylcyclopentane compounds

Publications (1)

Publication Number Publication Date
MX2020009462A true MX2020009462A (es) 2021-08-31

Family

ID=49582648

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020009462A MX2020009462A (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2016006299A MX367620B (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2019006959A MX2019006959A (es) 2013-11-15 2016-05-13 Procesos para la preparacion de compuestos de pirimidinilciclopentano.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016006299A MX367620B (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2019006959A MX2019006959A (es) 2013-11-15 2016-05-13 Procesos para la preparacion de compuestos de pirimidinilciclopentano.

Country Status (22)

Country Link
US (3) US9862689B2 (es)
EP (3) EP3068770B1 (es)
JP (4) JP6374503B2 (es)
KR (2) KR102493603B1 (es)
CN (3) CN112898210A (es)
AR (1) AR098427A1 (es)
AU (5) AU2014348570B2 (es)
CA (2) CA3207199A1 (es)
ES (2) ES2765511T3 (es)
HK (1) HK1223102A1 (es)
HR (2) HRP20231100T1 (es)
HU (1) HUE063095T2 (es)
IL (3) IL245636B (es)
MX (3) MX2020009462A (es)
MY (2) MY191759A (es)
NZ (1) NZ720805A (es)
PL (2) PL3656764T3 (es)
RU (1) RU2702355C1 (es)
SG (1) SG10201901578UA (es)
SI (1) SI3068770T1 (es)
WO (1) WO2015073739A1 (es)
ZA (2) ZA201603434B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2765511T3 (es) * 2013-11-15 2020-06-09 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
EP3197875B1 (en) 2014-09-26 2019-08-14 F.Hoffmann-La Roche Ag Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
CN115350192A (zh) 2016-08-10 2022-11-18 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
GB201802383D0 (en) * 2018-02-14 2018-03-28 Givaudan Sa Process

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545165B1 (en) 2000-02-04 2003-04-08 Roche Colorado Corporation Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
JP4219975B2 (ja) * 2005-05-24 2009-02-04 エフ．ホフマン−ラ ロシュ アーゲー （ｓ）−４−フルオロメチル−ジヒドロ−フラン−２−オンの製造
CN101198594A (zh) * 2005-06-22 2008-06-11 尼科梅德有限责任公司 用于制备生产三环苯并咪唑类的中间体的方法
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
BRPI0713555A2 (pt) * 2006-07-06 2012-03-20 Array Biopharma, Inc. ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
US7977078B2 (en) 2007-08-24 2011-07-12 Codexis, Inc. Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane
NZ586346A (en) * 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
MX2010007546A (es) 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
AR070176A1 (es) * 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
WO2010025238A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
CN102186972B (zh) 2008-08-29 2014-08-20 科德克希思公司 用于立体选择性生产(4s)-3-[(5s)-5-(4-氟苯基)-5-羟基戊酰基]-4-苯基-1，3-噁唑烷-2-酮的酮还原酶多肽
US20110054174A1 (en) * 2009-08-28 2011-03-03 Stephan Bachmann Process for the preparation of a glucokinase activator compound
RU2012148699A (ru) * 2010-04-16 2014-05-27 Дженентек, Инк. Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт
HUE036513T2 (hu) * 2011-04-01 2018-07-30 Genentech Inc AKT inhibitor vegyület és abirateron kombinációja terápiás kezelésekben való alkalmazásra
MA37647A1 (fr) * 2012-05-17 2016-03-31 Genentech Inc Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
BR112014028593A2 (pt) * 2012-05-17 2017-12-19 Genentech Inc forma amorfa de um composto de pirimidinil-ciclopentano inibidor de akt, composições e métodos dos mesmos"
CA2873654C (en) * 2012-05-17 2021-06-22 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
CA2873658C (en) 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
CN104487430B (zh) 2012-05-17 2016-08-24 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
ES2765511T3 (es) 2013-11-15 2020-06-09 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
EP3197875B1 (en) 2014-09-26 2019-08-14 F.Hoffmann-La Roche Ag Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

Also Published As

Publication number Publication date
BR112016011048A8 (pt) 2020-04-22
JP6634428B2 (ja) 2020-01-22
PL3656764T3 (pl) 2024-01-22
AR098427A1 (es) 2016-05-26
RU2016123365A (ru) 2017-12-18
MY191759A (en) 2022-07-14
SG10201901578UA (en) 2019-03-28
CN105899492A (zh) 2016-08-24
IL271331A (en) 2020-01-30
AU2019202461A1 (en) 2019-05-02
BR112016011048A2 (pt) 2017-08-08
CN110590606A (zh) 2019-12-20
CN110590606B (zh) 2023-02-17
ES2765511T3 (es) 2020-06-09
PL3068770T3 (pl) 2020-04-30
ZA202002611B (en) 2023-10-25
EP3656764B1 (en) 2023-07-05
MX2019006959A (es) 2019-08-01
EP3656764A1 (en) 2020-05-27
EP3068770A4 (en) 2017-04-19
EP4282973A3 (en) 2024-03-27
CA2930870A1 (en) 2015-05-21
AU2022275477A1 (en) 2023-01-05
JP7377828B2 (ja) 2023-11-10
AU2014348570B2 (en) 2019-02-28
US10435378B2 (en) 2019-10-08
US20180086722A1 (en) 2018-03-29
EP3068770A1 (en) 2016-09-21
HK1223102A1 (zh) 2017-07-21
WO2015073739A1 (en) 2015-05-21
AU2014348570A1 (en) 2016-06-09
IL245636B (en) 2019-12-31
MX367620B (es) 2019-08-28
JP6374503B2 (ja) 2018-08-15
CN112898210A (zh) 2021-06-04
CA3207199A1 (en) 2015-05-21
MY174153A (en) 2020-03-11
RU2019130505A (ru) 2020-02-18
US10858324B2 (en) 2020-12-08
IL281072A (en) 2021-04-29
JP2021100953A (ja) 2021-07-08
KR102493603B1 (ko) 2023-01-31
NZ720805A (en) 2022-01-28
KR20220139440A (ko) 2022-10-14
HRP20231100T1 (hr) 2023-12-22
US20200062717A1 (en) 2020-02-27
ES2957314T3 (es) 2024-01-17
US20160297773A1 (en) 2016-10-13
IL271331B (en) 2021-03-25
EP4282973A2 (en) 2023-11-29
EP3656764C0 (en) 2023-07-05
IL281072B (en) 2022-05-01
RU2702355C1 (ru) 2019-10-08
KR20160075816A (ko) 2016-06-29
AU2019202461B2 (en) 2021-01-14
AU2021202196A1 (en) 2021-05-06
MX2016006299A (es) 2017-02-22
US9862689B2 (en) 2018-01-09
IL245636A0 (en) 2016-06-30
AU2024205845A1 (en) 2024-09-05
JP2016539939A (ja) 2016-12-22
HRP20192340T1 (hr) 2020-04-03
CN105899492B (zh) 2021-08-24
CA2930870C (en) 2023-09-19
JP2019218384A (ja) 2019-12-26
HUE063095T2 (hu) 2023-12-28
ZA201603434B (en) 2020-08-26
SI3068770T1 (sl) 2020-02-28
JP2018052966A (ja) 2018-04-05
KR102698200B1 (ko) 2024-08-26
EP3068770B1 (en) 2019-10-23
JP6857219B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
MX2019006959A (es) Procesos para la preparacion de compuestos de pirimidinilciclopentano.
WO2014052506A3 (en) Facilitating affective feedback using wearable computing devices
EP3555953A4 (en) METHOD OF DESIGNING SLOT ANTENNAS FOR ELECTRONIC WEARABLE DEVICES AND CONDUCTIVE ENCLOSURES
MY193578A (en) Camera module and mobile terminal
PH12015501082A1 (en) Pyridine -2-amides useful as cb2 agonists
PH12014501597A1 (en) Hand-held device for electrically assisted dermal treatment
WO2014152055A3 (en) Sensing physiological characteristics with ear-related devices
NZ715920A (en) Pesticidal compositions and processes related thereto
IN2014DN08965A (es)
MX2015008061A (es) Sistema, metodo y aparato para el cuidado electronico de pacientes.
TWD166672S (zh) 電纜連接器之引線框外殼及電接觸件
BR112014016136A8 (pt) estruturas de pacote incluindo antenas distintas montadas em um dispositivo
WO2014195482A3 (en) Organic electronic device
EP2634809A3 (en) Field effect transistor
GB2490465A (en) Electrode treatment process for organic electronic devices
TWD167756S (zh) 電路連接器（四）
MX2018001527A (es) Cuerpo moldeado y dispositivo electrico que tiene un cuerpo moldeado para aplicaciones de alto voltaje.
WO2013117588A3 (en) A thin film for a lead for brain applications
DE102018214362B8 (de) Direkt am gerät zu montierender abschirmverbinder
EP2645498A3 (en) Electrical system enclosures
NZ711191A (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
JP1719683S (ja) 電気コネクタ
EP3939244A4 (en) ELECTRONIC DEVICE HAVING A CONDUCTIVE STRUCTURE OF A SUPPORT ELEMENT
BR112015030249A2 (pt) eletrodo médico, e garra de membro para um dispositivo ecg
TWD164746S (zh) 電連接器